Hims & Hers Health: What Investors Need to Know

Understanding Hims & Hers Health's Recent Performance

Hims & Hers Health, Inc. (HIMS) has recently captured significant attention in the investment community. As investors keep a close eye on its stock movements, it's essential to understand the factors that could influence its future performance.

Over the past month, shares of Hims & Hers Health have seen a substantial increase of +25.7%, far outpacing the Zacks S&P 500 composite's +3.4% gain. However, the broader Zacks Medical Info Systems industry, which includes Hims & Hers Health, has experienced a decline of 10% during the same period. This raises an important question: where is the stock headed in the near term?

Earnings Estimate Revisions and Their Impact

One of the key indicators for assessing a company's stock performance is the revision of earnings estimates. Analysts' changing projections reflect the latest business trends and can significantly impact investor sentiment.

For the current quarter, Hims & Hers Health is expected to report earnings of $0.18 per share, marking a +200% increase from the same period last year. The Zacks Consensus Estimate has remained stable over the last 30 days. For the current fiscal year, the consensus earnings estimate stands at $0.75, reflecting a year-over-year growth of +177.8%. This estimate has seen a slight change of +0.3% in the past month.

Looking ahead, the consensus earnings estimate for the next fiscal year is $1.03, indicating a +37.3% increase compared to what the company is expected to report a year ago. The estimate has also seen a minor change of +0.2% over the past month.

The Zacks Rank, a proprietary tool that leverages earnings estimate revisions, currently gives Hims & Hers Health a #1 rating, suggesting strong potential for outperforming the market in the near term.

Projected Revenue Growth

Revenue growth is a crucial factor in evaluating a company’s financial health. Without consistent revenue increases, long-term earnings growth becomes challenging.

Hims & Hers Health is projected to report sales of $551.84 million for the current quarter, representing a +74.8% year-over-year increase. For the current and next fiscal years, the revenue estimates stand at $2.35 billion and $2.86 billion, respectively, indicating growth rates of +58.9% and +21.8%.

Last Reported Results and Surprises

In its most recent quarter, Hims & Hers Health reported revenues of $586.01 million, a significant increase of +110.7% compared to the previous year. The EPS for the same period was $0.20, up from $0.05 a year ago.

Compared to the Zacks Consensus Estimate of $538.09 million, the reported revenues represented an impressive surprise of +8.9%. The EPS surprise was even more substantial at +66.67%.

Over the last four quarters, Hims & Hers Health has exceeded consensus EPS estimates twice and has consistently beaten revenue expectations each time.

Valuation Considerations

Valuation plays a critical role in investment decisions. Determining whether a stock is fairly valued, overvalued, or undervalued is essential for assessing its future performance.

The Zacks Value Style Score evaluates both traditional and unconventional valuation metrics, categorizing stocks into five groups from A to F. Hims & Hers Health has been assigned a D grade, indicating that it is trading at a premium relative to its peers.

Conclusion

The information provided here offers valuable insights into the factors influencing Hims & Hers Health's stock performance. While market buzz around the company is notable, its Zacks Rank #1 suggests a positive outlook for near-term gains. Investors should consider these factors when making informed decisions about their portfolios.